John P. Kirkpatrick

Malignant and benign tumors of the brain, spine and base of skull. Mathematical modelling of tumor metabolism, mass transfer and the response to ionizing radiation. Enhancing clinical outcome in stereotactic radiosurgery, fractionated stereotactic radiotherapy and stereotactic body radiotherapy.

Current Appointments & Affiliations

Professor of Radiation Oncology · 2018 - Present Radiation Oncology, Clinical Science Departments

Professor in Neurosurgery · 2018 - Present Neurosurgery, Neurosurgery

Member of the Duke Cancer Institute · 2000 - Present Duke Cancer Institute, Institutes and Centers

In the News

Published July 10, 2025

How Duke is Transforming Care for Brain and Spine Metastasis

View All News

Recent Publications

Neurocognitive outcomes in patients with brain metastases: a systematic review.

Journal Article Lancet Oncol · December 2025 Multimodality therapy, including surgery, radiotherapy, and systemic therapy, has significantly improved overall survival for patients with brain metastases. However, treatment-related neurocognitive sequelae remain a major challenge in survivorship. Altho ... Full text Link to item Cite

Management outcomes for biopsy-proven radiation necrosis in patients with brain metastases in the era of immune-checkpoint blockade.

Journal Article J Neurooncol · October 2025 PURPOSE: Immunotherapy and stereotactic radiosurgery (SRS) are frequently combined in the management of brain metastases from non-small cell lung cancer (NSCLC) and melanoma. However, concurrent SRS and dual immune-checkpoint inhibition (ICPI) elevate the ... Full text Open Access Link to item Cite

Clinical Parameters Associated With Intracranial Progression Burden Following an Initial Stereotactic Radiosurgery Course in a Multi-institutional Brain Metastases Cohort.

Journal Article Adv Radiat Oncol · September 2025 PURPOSE: Following initial stereotactic radiosurgery (SRS), risk factors for high-burden intracranial progression (ICP) necessitating whole brain radiation remain poorly characterized. We hypothesize that specific clinical parameters at initial SRS are ass ... Full text Link to item Cite

View All Publications

Recent Grants

PHASE 1, SINGLE-CENTER, DOSE-ESCALATING, OPEN-LABEL, SAFETY CLINICAL TRIAL OF PARENTERAL ASCORBATE-MEGLUMINE AS A NOVEL MAGNETIC RESONANCE IMAGING-GUIDED ADJUNCTIVE THERAPEUTIC FOR STEREOTACTIC RADIOSURGERY

Clinical TrialPrincipal Investigator · Awarded by LadeRx · 2023 - 2026

BMX-001 AS A THERAPEUTIC AGENT FOR TREATMENT OF MULTIPLE BRAIN METASTASES

Clinical TrialPrincipal Investigator · Awarded by BioMimetix JV LLC · 2018 - 2023

Developing knowledge models to enable rapid learning in radiation therapy

ResearchCo Investigator · Awarded by National Institutes of Health · 2016 - 2020

View All Grants

Education, Training & Certifications

University of Texas Health Science Center San Antonio · 1999 M.D.

Rice University · 1978 Ph.D.